


FORM PTO-1449 (REV.7-80)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 53208AUSM1	APPLICATION NO. 10/815,342
 INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANTS Abdul-Ahad et al.			
			FILING DATE April 1, 2004	GROUP ART UNIT Not Yet Assigned 1647		
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JS	1. 4,588,585	13May1986	Mark et al.			28SEP1984
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
JS	2.	Knobler, R.L. et al., "Systemic Recombinant Human Interferon- β Treatment of Relapsing-Remitting Multiple Sclerosis: Pilot Study Analysis and Six-Year Follow-Up", <i>J. Interferon Res.</i> , (1993) 13:333-349				
	3.	Rice, G.P.A. et al., "Ibuprofen treatment versus gradual introduction of interferon β -1b in patients with MS", <i>Neurology</i> , (1999) 52:1893-1895				
	4.	McCormack, P.L. et al., "Interferon- β -1b, A Review of its Use in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis", <i>CNS Drugs</i> , 2004:18(8) 521-546				
	5.	Cook, S.D., "Advancing treatment with interferon beta-1b (Betaferon®/Betaseron®) in the next decade. Thinking beyond the standard dose", <i>J. Neurol</i> (2003) 250(4) IV/15-IV/20				
	6.	Durelli, L. "Dose and frequency of interferon treatment matter INCOMIN and OPTIMS", <i>J. Neurol</i> . (2003) 250 (4): IV-/IV/14				
	7.	Bayas, A. et al., Lessons from 10 years of interferon beta-1b (Betaferon®/Betaseron®) treatment", <i>J. Neurol</i> . (2003) 250(4): IV/3-IV/8				
	8.	Gottesman, M.H., "Interferon beta-1b (Betaferon®/Betaferon®) is well tolerated at double the currently used dose: Interferon dose escalation assessment of safety (IDEAS) " AAN Poster (2003)				
	9.	Gottesman, M. et al., "Results from the IDEAS (Interferon Dose Escalation Assessment and Safety) study: 500 ug dose interferon beta-1b (Betaferon®/Betaseron®) in multiple sclerosis treatment", 19 th ECTRIMS, Milan Italy 17-20 Sept 2003				
	10.	Hurwitz, B.J. et al., "Safety and tolerability of 500 μ g versus 250 μ g of interferon beta-1b (Betaferon®/ Betaseron®) – First stage of the BEYOND (Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose) programme", 19 th ECTRIMS, Milan Italy 17-20 Sept 2003				
↓	11.	Verdun, E. et al., "Evaluation of High-Dose Interferon Beta-1B in Relapsing-Remitting MS Non-Responder Patients: The Optimis Trial Safety Data", 2003 AAN Poster				
EXAMINER /Jegatheesan Seharaseyon/			DATE CONSIDERED 02/27/2007			